Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
37 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Tom Baker Centre
Calgary, Canada
- Juravinski Cancer Center
Hamilton, Canada
- Chum Hôpital Notre Dama
Montreal, Canada
- Jewish General Hospital
Montreal, Canada
- Centre Hospitalier Départemental Les Oudairies
La Roche-sur-Yon, France
- Centre Léon Berard
Lyon, France
- Clinique Hartmann
Neuilly-sur-Seine, France
- Institut Curie
Paris, France
- Institut Gustave Roussy
Villejuif, France
- Charité Campus Benjamin Franklin
Berlin, Germany
- Universitatsklinikum Erlangen
Erlangen, Germany
- Universitatsklinikum Hamburg Eppendorf
Hamburg, Germany
- Cork University Hospital
Cork, Ireland
- Mater Misericordiae University Hospital
Dublin, Ireland
- Mater Private Hospital
Dublin, Ireland
- St Jame'S Hospital
Dublin, Ireland
- Waterford Regional Hospital
Waterford, Ireland
- Kaplan Medical Center
Rehovot, Israel
- Hospital Universitario de Tenerife
La Laguna (Santa Cruz de Tenerife), Spain
- Hospital U 12 de Octubre
Madrid, Spain
- Hospital Universitario Virgen Macarena de Sevilla
Seville, Spain
- Comprehensive Blood and Cancer Center
Bakersfield, California, United States
- St Jude Heritage Healthcare
Fullerton, California, United States
- Wilshire Oncology Medical Group Inc
La Verne, California, United States
- Cedars Sinai Medical Center
Los Angeles, California, United States
- Lac/usc Medical Center
Los Angeles, California, United States
- Ucla
Los Angeles, California, United States
- University of Southern California/ Norris Comprehensive Cancer Center
Los Angeles, California, United States
- North Valley Hematology/ Oncology Medical Group
Northridge, California, United States
- Ventura County Hematology Oncology Specialists
Oxnard, California, United States
- Central Hematology Oncology Medical Group Inc.
Pasadena, California, United States
- University of Colorado
Aurora, Colorado, United States
- University of Chicago
Chicago, Illinois, United States
- Cancer Center of Kansas
Wichita, Kansas, United States
- St Joseph Mercy Health System
Ann Arbor, Michigan, United States
- Mayo Clinic
Rochester, Minnesota, United States
- Comprehensive Cancer Centre of Nevada
Henderson, Nevada, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jan 2009
- Primary completion
- 31 May 2013
- Completion
- 31 May 2013
- Last update posted
- 11 Jan 2016
- Registered enrollment
- 61
- Registry id
- NCT00719212
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.